What do systematic reviews say?

Indacaterol vs placebo

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 5001 participants
  High

Indacaterol vs long‐acting beta2‐agonist alone

Indacaterol showed no clear difference in number of participants experiencing at least 1 exacerbation… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1.07 [0.86, 1.33]
  2 studies · 1869 participants
  Moderate

Indacaterol vs long‐acting beta2‐agonist alone

Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1.02 [0.79, 1.32]
  4 studies · 3266 participants
  Moderate

Indacaterol vs long‐acting beta2‐agonist alone

Indacaterol showed no clear difference in mortality Deaths compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1 [0.31, 3.28]
  4 studies · 3266 participants
  Moderate

Indacaterol vs placebo

Indacaterol leads to higher number of participants with a clinically significant improvement in… compared with placebo (high certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1.64
  9 studies · 4906 participants
  High

Indacaterol vs placebo

Indacaterol leads to higher number of participants with clinically significant improvement in… compared with placebo (high certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1.96 [1.73, 2.22]
  8 studies · 4577 participants
  High

Indacaterol vs placebo

Indacaterol leads to lower number of participants experiencing 1 or more exacerbations compared with placebo (high certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 0.81 [0.7, 0.94]
  7 studies · 4807 participants
  High

Indacaterol vs placebo

Indacaterol showed no clear difference in serious adverse events compared with placebo (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1 [0.82, 1.23]
  9 studies · 6065 participants
  Moderate

Indacaterol vs placebo

Indacaterol showed no clear difference in mortality compared with placebo (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 0.42 [0.16, 1.08]
  9 studies · 5694 participants
  Moderate

Indacaterol vs long‐acting beta2‐agonist alone

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2708 participants
  High

Indacaterol vs long‐acting beta2‐agonist alone

Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1.07 [0.87, 1.32]
  2 studies · 1520 participants
  Moderate

Indacaterol vs long‐acting beta2‐agonist alone

Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1.11 [0.94, 1.32]
  3 studies · 2536 participants
  Moderate